Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Haematological cancer

Carfilzomib is superior to bortezomib in rMM

Nature Reviews Clinical Oncology volume 13, page 590 (2016)Cite this article

Subjects

Access through your institution
Buy or subscribe

Patients with relapsed multiple myeloma (rMM) often receive multiple lines of therapy, which can make identification of the true efficacy of new agents in clinical trials challenging. Now, a subgroup analysis of data from the ENDEAVOR study reveal that the protesome inhibitor carfilzomib has superior efficacy to that of bortezomib (both in the presence of dexamethasone), regardless of the number of lines of prior treatment, or prior exposure to lenalidomide. Treatment with carfilzomib also resulted in a higher response rate than treatment with bortezomib, again regardless of the type or extent of pretreatment, with similar toxicity profiles observed. These data indicate that carfilzomib is superior to bortezomib in patients with rMM. The findings of these subgroup analyses further support the results of the ENDEAVOR study.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Moreau, P. et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia http://dx.doi.org/10.1038/leu.2016.186 (2016)

Download references

Authors
  1. Peter Sidaway
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sidaway, P. Carfilzomib is superior to bortezomib in rMM. Nat Rev Clin Oncol 13, 590 (2016). https://doi.org/10.1038/nrclinonc.2016.136

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.136

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing